• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Savara gets $1.7 million for AeroVanc development

Cystic Fibrosis Foundation Therapeutics (CFFT) has awarded Savara Pharmaceuticals $1.7 million for further development of AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. CFFT is a nonprofit affiliate of the Cystic Fibrosis Foundation that supports discovery and development of therapies for CF.

AeroVanc, which is delivered by a capsule-based DPI, is in Phase 2 development for the treatment of CF patients and has been granted orphan drug designation by the FDA for that use. Patient enrollment in an 80-person randomized, double-blind, placebo-controlled study began earlier this year and is ongoing. Savara is also developing AeroVanc for the treatment of non-CF bronchiectasis and ventilator assisted pneumonia (VAP).

Savara CEO Rob Neville commented, “The support of the CF Foundation is yet another acknowledgment that AeroVanc addresses an unmet need for people with CF suffering from MRSA infection. The $6 million in support that Savara has received from the CF Foundation and the National Institutes of Health not only provides critical funding to advance the AeroVanc program, but is also a strong endorsement of the quality and promise of our program.”

Read the Savara press release.

Share

published on October 17, 2013

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews